research use only

Tizanidine Adrenergic Receptor agonist

Cat.No.S5537

Tizanidine is an imidazoline derivative and a centrally acting α2 adrenergic agonist used as a muscle relaxant for therapy of acute muscle spasms and chronic spasticity.
Tizanidine Adrenergic Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 253.71

Quality Control

Batch: S553701 DMSO]50 mg/mL]false]Water]15 mg/mL]false]Ethanol]6 mg/mL]false Purity: 98.4%
98.4

Chemical Information, Storage & Stability

Molecular Weight 253.71 Formula

C9H8ClN5S

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 51322-75-9 -- Storage of Stock Solutions

Synonyms N/A Smiles C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl

Solubility

In vitro
Batch:

DMSO : 50 mg/mL (197.07 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 15 mg/mL

Ethanol : 6 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
α2 adrenergic receptor [1]
In vitro
Like clonidine, it has sedative, anxiolytic, and analgesic properties, but it has a shorter duration of action and less effect on heart rate and blood pressure[1].
In vivo
Tizanidine is shown to significantly reduce pain and tissue tenderness and to improve the quality of sleep[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01844674 Completed
Malignant Melanoma Neoplasms
Hoffmann-La Roche
September 2 2013 Phase 1
NCT01839279 Completed
Spasticity
Acorda Therapeutics
April 2013 Phase 2
NCT01405950 Terminated
Spasticity Due to Cerebral Palsy
Acorda Therapeutics|Syneos Health
May 2011 Phase 1
NCT01065987 Completed
Healthy
Dr. Reddy''s Laboratories Limited
September 2001 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map